Imagine a smart plug for the chest that lets doctors drain fluid or air instantly without risking internal organ damage. It acts like a secure gateway that fits any patient's body size automatically and locks the drainage tube in place. This means life-saving treatment can happen in the field rather than waiting until the patient reaches a hospital.
Current chest tube treatments are static and invasive, making them unusable for first responders in the field and prone to high complication rates (20-40%) in hospitals.
A self-fixating drainage port including 9 industrial moulds and 21 polymer components, with 300 sets produced for verification and validation testing.
If you are an equipment provider dealing with the 'Golden Hour' window where 80% of patients can be saved if treated within 1 hour — this project developed a self-fixating drainage port that enables instant tube insertion in the field.
If you are a distributor dealing with the 20-40% complication rate of traditional chest tubes — this project developed a sealing system that prevents dislodgement and leakage, reducing the need for costly re-interventions.
If you are a health system dealing with €2.6Bn in costs associated with tube replacements in Europe — this project developed a cost-efficient drainage port that eliminates the need for extra fixation accessories.
It reduces costs by eliminating the need for accessories for insertion, fixation, or removal, and by decreasing the frequency of expensive tube replacements, which cost Europe about €2.6Bn.
Yes, the project has completed the transfer from R&D to production, including the manufacture of 9 polymer moulds and all metal components.
Based on available project data, the technology is developed by Vigor Medical Technologies Ltd, but specific patent or licensing terms are not detailed.
The company has established and is implementing a full quality system according to ISO 13485.
The project period runs from 2023-03-01 to 2025-11-30, with current focus on clinical validation and scaling-up.
The project is led by a single SME, Vigor Medical Technologies Ltd from Israel. With a 100% industry ratio and no university or research partners, the consortium is lean and focused entirely on commercialization and production scaling rather than basic research.
Contact Vigor Medical Technologies Ltd regarding C-LANT clinical validation
Contact us to explore licensing or distribution partnerships for C-LANT.
